News | Published:

CRISPR target prediction remains blunt tool for clinical applications

Nature Biotechnologyvolume 37pages204205 (2019) | Download Citation


Computational approaches to predict gene editing repair by CRISPR endonucleases remain a work in progress.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 20 March 2019

    In the version of this article initially published, we reported that Sangamo’s SB-318 had failed to change baseline leukocyte α-l-iduronidase in a phase 1/2 trial. The drug failed to change baseline plasma α-l-iduronidase but did increase leukocyte α-l-iduronidase to within the normal range. The error has been corrected in the HTML and PDF versions of the article.

Author information


  1. Cambridge, UK

    • John Hodgson


  1. Search for John Hodgson in:

Corresponding author

Correspondence to John Hodgson.

About this article

Publication history


Issue Date


Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing